University Hospitals Birmingham NHS Foundation Trust
Welcome,         Profile    Billing    Logout  
 97 Trials 
833 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rea, Daniel
NOSTRA, NCT04118192: -Feasibility Study: A Study Looking at Ultrasound Guided Biopsies for Breast Cancer

Active, not recruiting
N/A
72
Europe
Tumour bed core biopsy
University of Birmingham, Roche Pharma AG, Cancer Research UK
Breast Cancer
12/25
12/25
Jones, Robert
DETERMINE, NCT05768178: Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

Recruiting
2/3
30
Europe
Vemurafenib, Zelboraf, Cobimetinib, Cotellic
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Melanoma, Thyroid Cancer, Papillary, Ovarian Neoplasms, Colorectal Neoplasms, Laryngeal Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioma, Multiple Myeloma, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic
10/29
10/29
CRUKD/21/004, NCT05722886: DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

Recruiting
2/3
825
Europe
Alectinib, Alecensa, Atezolizumab, Tecentriq, Entrectinib, Rozlytrek, Trastuzumab in combination with pertuzumab, Herceptin in combination with Perjeta, Vemurafenib in combination with cobimetinib, Zelboraf in combination with Cotellic
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy
10/29
10/29
DETERMINE, NCT05786716: Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations

Recruiting
2/3
30
Europe
Trastuzumab, Herceptin, Pertuzumab, Perjeta
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Colorectal Neoplasms, Urinary Bladder Neoplasm, Gallbladder Neoplasms, Salivary Gland Neoplasm, Lung Neoplasm, Pancreatic Neoplasm, Ovarian Neoplasms, Prostatic Neoplasm, Skin Neoplasm
10/29
10/29
DETERMINE, NCT05770102: Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

Recruiting
2/3
30
Europe
Atezolizumab, Tecentriq
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Colorectal Neoplasms, Endometrial Neoplasms, Melanoma
10/29
10/29
DETERMINE, NCT05770037: Trial Treatment Arm 01: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers

Recruiting
2/3
30
Europe
Alectinib, Alecensa
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Anaplastic Large Cell Lymphoma, Lymphoma, Renal Cell Carcinoma, Neuroblastoma
10/29
10/29
DETERMINE, NCT05770544: Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers.

Recruiting
2/3
30
Europe
Entrectinib, Rozlytrek
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Brain Neoplasms, Melanoma, Glioma
10/29
10/29
KEYNOTE-D78, NCT04879329: A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Recruiting
2
332
Europe, Canada, Japan, US, RoW
disitamab vedotin, RC48-ADC, pembrolizumab, KEYTRUDA®
Seagen Inc., Merck Sharp & Dohme LLC
Urothelial Carcinoma
11/26
05/28
FAKTION, NCT01992952: Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer

Checkmark From P1b/2 FAKTION trial for advanced ER+/HER2- breast cancer at ASCO 2019 [screenshot]
Jun 2019 - Jun 2019: From P1b/2 FAKTION trial for advanced ER+/HER2- breast cancer at ASCO 2019 [screenshot]
Active, not recruiting
1b/2
149
Europe
AZD5363, Placebo, Fulvestrant
Velindre NHS Trust, AstraZeneca, Cenduit LLC, Covance, Cardiff and Vale University Health Board
Estrogen Receptor Positive Breast Cancer
03/19
12/23
NCT05944237: HTL0039732 in Participants with Advanced Solid Tumours

Recruiting
1/2
150
Europe
HTL0039732 Capsules, HTL0039732 Capsules and atezolizumab infusion
Cancer Research UK, Nxera Pharma UK Limited
Neoplasms, Prostatic Neoplasms, Castration-Resistant, Stomach Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Colorectal Neoplasms, Pancreatic Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasms, Mesothelioma, Malignant, Uterine Cervical Neoplasms, Kidney Neoplasms, Sarcoma, Pheochromocytomas
09/26
09/26
NCT04630262: ATTUNE Cementless FB Tibial Base Clinical Study

Terminated
N/A
80
US
ATTUNE Cementless CR Fixed Bearing, ATTUNE Cementless PS Fixed Bearing
DePuy Orthopaedics
Osteoarthritis of the Knee
03/23
03/23
WAVE, NCT04540302: The Merit WRAPSODY AV Access Efficacy Study

Active, not recruiting
N/A
357
Europe, Canada, US, RoW
Merit WRAPSODY Endovascular Stent Graft, PTA
Merit Medical Systems, Inc.
Venous Stenosis, Venous Occlusion
02/24
01/26
NCT05527483: Digital PET/CT Using [Ga-68]PSMA vs. [F-18]NaF for Evaluation of Osseous Metastatic Involvement in Prostate Cancer Patients

Completed
N/A
32
US
[68Ga]PSMA, Flourine-18 [F-18] Sodium Fluoride (NaF), PET/CT
University Hospitals Cleveland Medical Center
Prostate Cancer
10/22
10/22
Mossie-GO, NCT06232954: Evaluation of the Protective Efficacy of a Spatial Repellent to Reduce Malaria Prevalence in Uganda

Recruiting
N/A
5600
RoW
Mossie-Go containing treated transfluthrin disc, Mossie-Go containing untreated blank disc
Africa Power Limited, Malaria Consortium, ARCTECH INNOVATION LIMITED
Malaria, Mosquito-Borne Disease
09/25
09/25
NCT04682665: Prebiotic Effect of Eicosapentaenoic Acid Treatment for Colorectal Cancer Liver Metastases

Completed
N/A
81
Europe
Icosapent Ethyl Oral Capsule, Placebo
University of Leeds, National Cancer Institute (NCI), Massachusetts General Hospital, Massachusetts Institute of Technology, Harvard School of Public Health (HSPH), University of Bradford
Colon Cancer Liver Metastasis
07/24
07/24
WRAP, NCT05062291: Merit SODY™ Endoprosthesis for Treatment of Stenosis or Occlusion

Recruiting
N/A
500
Europe, RoW
Merit WRAPSODY Endovascular Stent Graft
Merit Medical Systems, Inc.
Venous Stenosis, Venous Occlusion
12/25
07/27
NCT06797193: Ultrasound with Subharmonic Imaging and Subharmonic Aided Pressure Estimation (SHAPE) to Identify Portal Hypertension

Not yet recruiting
N/A
60
US
Electronic Health Record Review, Liver Biopsy, Biopsy of Liver, Medical Device Usage and Evaluation, Perflutren Lipid Microspheres, Definity, Ultrasound Imaging, 2-Dimensional Grayscale Ultrasound Imaging, 2-Dimensional Ultrasound Imaging, 2D-US, Ultrasonography, Ultrasound, Ultrasound Test, Ultrasound, Medical, US
Mayo Clinic
Cirrhosis
01/27
01/27
TARGET National, NCT04723316: Tumour Characterisation to Guide Experimental Targeted Therapy - National

Recruiting
N/A
6000
Europe
The Christie NHS Foundation Trust
Cancer
01/26
01/28
NCT04907240: Observational GORE® VIABAHN® Endoprosthesis With PROPATEN Bioactive Surface Global Registry

Recruiting
N/A
614
Europe
GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
W.L.Gore & Associates
Peripheral Artery Disease, Popliteal Aneurysm, Hemodialysis Access, Visceral Artery Aneurysms, Trauma Injury
10/26
10/35
ACTRN12619000470190p: FLASH.V: Flash Glucose Monitoring and Surgery in the Hepatopancreaticobiliary (HPB) Surgery and Liver Transplant Population - Verification Study

Not yet recruiting
N/A
100
 
University of Melbourne: Department of Surgery , Austin Health Liver Transplant Unit, Austin Medical Research Fund
Liver Transplantation ; Anaesthetics
 
 
ACTRN12619000470190: FLASH.V: Flash Glucose Monitoring and Surgery in the Hepatopancreaticobiliary (HPB) Surgery and Liver Transplant Population - Verification Study

Not yet recruiting
N/A
100
 
University of Melbourne: Department of Surgery , Austin Health Liver Transplant Unit, Austin Medical Research Fund
Liver Transplantation , Anaesthetics
 
 
PINCER, NCT05650125: A Platform Study for solId orgaN CancERs

Recruiting
N/A
2000
Europe
Biosampling
University of Liverpool, Countess of Chester NHS Foundation Trust, Liverpool University Hospitals NHS Foundation Trust, Clatterbridge Centre for Oncology, Liverpool Heart and Chest Hospital NHS Foundation Trust, Liverpool Womens Hospital
Cancer, Surgery
01/30
01/30
Ford, Daniel
PREVENTABLE, NCT04262206: Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults

Recruiting
4
20000
US
Atorvastatin 40 Mg Oral Tablet, Lipitor, Placebo oral tablet
Duke University, National Institute on Aging (NIA), National Heart, Lung, and Blood Institute (NHLBI), Wake Forest University Health Sciences
Cognitive Impairment, Mild, Dementia, Cardiovascular Diseases
12/26
12/26
NCT03568656 / 2018-000285-10: Study to Evaluate CCS1477 in Advanced Tumours

Recruiting
1/2
350
Europe, US
CCS1477, Abiraterone acetate, Enzalutamide, Darolutamide, Olaparib, Atezolizumab
CellCentric Ltd.
Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer, Non-small Cell Lung Cancer, Advanced Solid Tumors
12/24
12/24
A2Q, NCT04720625: Adapt2Quit - An Adaptive Motivational System for Socio-Economically Disadvantaged Smokers

Recruiting
N/A
750
US
Adapt2Quit, Control
University of Massachusetts, Worcester, National Institutes of Health (NIH), National Cancer Institute (NCI), Johns Hopkins University, Baystate Health
Tobacco Smoking
10/24
03/25
Harper, Lorraine
REACTIVAS, NCT04916704: Subclinical Cytomegalovirus Reactivation in Acute ANCA-associated Vasculitis

Active, not recruiting
N/A
70
Europe
University Hospital Birmingham NHS Foundation Trust, Merck Sharp & Dohme LLC
ANCA Associated Vasculitis
12/24
12/25
Middleton, Gary W
PRESERVE-003, NCT05671510: ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

Active, not recruiting
3
600
Europe, Canada, US, RoW
Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere
OncoC4, Inc., BioNTech SE
Non Small Cell Lung Cancer
06/26
06/27
DETERMINE, NCT05768178: Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

Recruiting
2/3
30
Europe
Vemurafenib, Zelboraf, Cobimetinib, Cotellic
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Melanoma, Thyroid Cancer, Papillary, Ovarian Neoplasms, Colorectal Neoplasms, Laryngeal Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioma, Multiple Myeloma, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic
10/29
10/29
CRUKD/21/004, NCT05722886: DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

Recruiting
2/3
825
Europe
Alectinib, Alecensa, Atezolizumab, Tecentriq, Entrectinib, Rozlytrek, Trastuzumab in combination with pertuzumab, Herceptin in combination with Perjeta, Vemurafenib in combination with cobimetinib, Zelboraf in combination with Cotellic
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy
10/29
10/29
DETERMINE, NCT05786716: Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations

Recruiting
2/3
30
Europe
Trastuzumab, Herceptin, Pertuzumab, Perjeta
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Colorectal Neoplasms, Urinary Bladder Neoplasm, Gallbladder Neoplasms, Salivary Gland Neoplasm, Lung Neoplasm, Pancreatic Neoplasm, Ovarian Neoplasms, Prostatic Neoplasm, Skin Neoplasm
10/29
10/29
DETERMINE, NCT05770102: Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

Recruiting
2/3
30
Europe
Atezolizumab, Tecentriq
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Colorectal Neoplasms, Endometrial Neoplasms, Melanoma
10/29
10/29
DETERMINE, NCT05770037: Trial Treatment Arm 01: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers

Recruiting
2/3
30
Europe
Alectinib, Alecensa
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Anaplastic Large Cell Lymphoma, Lymphoma, Renal Cell Carcinoma, Neuroblastoma
10/29
10/29
DETERMINE, NCT05770544: Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers.

Recruiting
2/3
30
Europe
Entrectinib, Rozlytrek
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Brain Neoplasms, Melanoma, Glioma
10/29
10/29
PePS2, NCT02733159 / 2015-002241-55: Pembrolizumab in Patients With Non-Small Cell Lung Cancer and a Performance Status 2

Active, not recruiting
2
62
Europe
pembrolizumab, MK-3475
University of Birmingham, Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
02/23
02/24
ANICCA, NCT03981146 / 2018-000318-39: A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer

Active, not recruiting
2
35
Europe
Nivolumab, Opdivo
University of Birmingham, Bristol-Myers Squibb
Colorectal Cancer
10/24
10/24
NCT02664935 / 2014-000814-73: National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Checkmark Results from National Lung Matrix Trial
Oct 2019 - Oct 2019: Results from National Lung Matrix Trial
Checkmark NCRI 2016
Dec 2016 - Dec 2016: NCRI 2016
Active, not recruiting
2
423
Europe
AZD4547, Vistusertib, AZD2014, Palbociclib, Crizotinib, Selumetinib, AZD6244, Docetaxel, AZD5363, Osimertinib, AZD9291, Durvalumab, MEDI4736, Sitravatinib, MGCD516, AZD6738
University of Birmingham, Cancer Research UK, AstraZeneca, Pfizer, Experimental Cancer Medicine Centres, Mirati Therapeutics Inc.
Non-Small Cell Lung Cancer, Carcinoma, Squamous Cell, Adenocarcinoma
09/24
09/24
NCT04785365: Long-Term Follow-Up Study of Patients Receiving ATL001

Terminated
2
1
Europe
Biological: ATL001
Achilles Therapeutics UK Limited
Melanoma, Advanced Non Small Cell Lung Cancer
10/23
10/23
CRUKD/17/009, NCT03486730 / 2016-004633-24: BT1718 in Patients with Advanced Solid Tumours.

Hourglass Jun 2022 - Dec 2022 : Updated data for solid tumors
Completed
1/2
72
Europe
BT1718
Cancer Research UK, Bicycle Therapeutics
Advanced Solid Tumours, Non-Small Cell Lung Cancer, Non-Small Cell Lung Sarcoma, Oesophageal Cancer
11/23
11/23
CRUKD/20/001, NCT04908111: A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1

Suspended
1/2
103
Europe
ChAdOx1-MAGEA3-NYESO, MVA-MAGEA3, Standard of care treatment, MVA-NYESO
Cancer Research UK, Barinthus Biotherapeutics
Non-small Cell Lung Cancer (NSCLC), Esophageal Neoplasms
12/27
12/27
CRUKD/17/003, NCT03371485: AST-VAC2 Vaccine in Patients With Non-small Cell Lung Cancer

Completed
1
9
Europe
AST-VAC2
Cancer Research UK
Advanced Non-small Cell Lung Cancer
08/22
08/22
Leyva, Francisco
CRT-DRIVE, NCT05327062: Cardiac Resynchronization Therapy Delivery Guided Non-Invasive Electrical and Venous Anatomy Assessment

Recruiting
N/A
150
Europe, US
CRT implantation guided by XSpline, a non-invasive electrical and venous anatomy assessment
XSpline S.p.A.
Cardiac Resynchronization Therapy, Chronic Heart Failure, Left Bundle-Branch Block
03/25
09/25
VECTOR-HF, NCT03775161: V-LAP™ Left Atrium Monitoring systEm for Patients With Chronic sysTOlic & Diastolic Congestive heaRt Failure

Active, not recruiting
N/A
45
Europe
V-LAP™ System, Echocardiography
Vectorious Medical Technologies Ltd., Horizon 2020 - European Commission
Heart Failure
12/24
12/24
Mehanna, Hisham
EPIC-iENE DATA, NCT05936502: Ascertaining the Radiologic Prognostic Importance of Extranodal Extension on Imaging (iENE) in Head and Neck Cancer

Completed
N/A
3500
Europe, US, RoW
Extranodal extension
Head and Neck Cancer International Group
Head and Neck Squamous Cell Carcinoma, Extranodal Extension, Human Papilloma Virus Related Carcinoma
08/23
09/23
BD4QoL, NCT05315570: Big Data for Quality of Life in Head and Neck Cancer

Recruiting
N/A
420
Europe
BD4QoL platform
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, University of Birmingham, University Hospital Birmingham NHS Foundation Trust, Dotsoft Olokliromenes Efarmoges Diadiktioy kai Vaseon Dedomenon AE, IBM Ireland limited, INETUM, Multimed Engineers srl, Regione Lombardia, Universidad de la Iglesia de Deusto Entidad Religiosa, Universidad Politecnica de Madrid, University of Milan, University of Oslo, Johannes Gutenberg University Mainz, Aria S.p.A., University of Bristol, Casa Sollievo della Sofferenza IRCCS
Head and Neck Cancer, Survivorship, Quality of Life
09/24
06/25
Adams, David R
NCT01675440: Safety & Efficacy Study of the Medtronic CoreValve® System-Treatment of Symptomatic Severe Aortic Stenosis With Significant Comorbidities in Extreme Risk Subjects Who Need Aortic Valve Replacement

Active, not recruiting
N/A
782
US
Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
Medtronic Cardiovascular
Severe Aortic Stenosis
12/16
01/26
SURTAVI, NCT01586910: Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement ().

Active, not recruiting
N/A
1746
Europe, Canada, US
Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI), Surgical Aortic Valve Replacement (SAVR), Medtronic CoreValve® Evolut R System Transcatheter Aortic Valve Implantation (TAVI)
Medtronic Cardiovascular
Severe Aortic Stenosis
07/18
11/26
NCT03645447: The Taste-Mood Diagnostic Study

Recruiting
N/A
240
Europe
Taste test
Ranvier Health Ltd
Depression
12/24
02/25
NCT02539329: Characterization of Anti-FGFR3 Antibodies

Completed
N/A
251
Europe
Neurological assessment and Blood sample
Centre Hospitalier Universitaire de Saint Etienne
Sensory Peripheral Neuropathy
11/21
01/22
ReChord, NCT02803957: Randomized Trial of the Neochord DS1000 System Versus Open Surgical Repair

Recruiting
N/A
585
US
NeoChord DS1000, Surgical Mitral Valve Repair
NeoChord
Mitral Valve Insufficiency
07/22
07/27
NCT03904147: TRILUMINATE Pivotal Trial

Active, not recruiting
N/A
572
Europe, Canada, US
TriClipTM Device
Abbott Medical Devices
Tricuspid Regurgitation
11/22
04/29
PERIGON, NCT02088554: Pivotal Trial

Active, not recruiting
N/A
1312
Europe, Canada, US
Model 400 aortic valve bioprosthesis
Medtronic Cardiac Surgery, Medtronic
Aortic Stenosis
04/23
12/35
ICE-AFIB, NCT03732794: AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment

Active, not recruiting
N/A
150
US
AtriCure CryoICE & AtriClip LAA Exclusion
AtriCure, Inc.
Atrial Fibrillation (AF), Persistent Atrial Fibrillation, Longstanding Persistent Atrial Fibrillation
06/24
06/26
NCT04433065: TTVR Early Feasibility Study

Recruiting
N/A
15
US
Intrepid™ TTVR System
Medtronic Cardiovascular
Tricuspid Regurgitation
07/25
07/31
APOLLO, NCT03242642: Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.

Recruiting
N/A
1056
Europe, Canada, US
Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)
Medtronic Cardiovascular
Mitral Valve Regurgitation
10/26
09/36
Moody, William E
PROTEUS, NCT05028179: Evaluating the Use of Artificial Intelligence to Support Stress Echocardiography Testing for Heart Disease

Active, not recruiting
N/A
2338
Europe
EchoGo
Ultromics Ltd, University of Oxford, Academic Health Science Centres, National Institute for Health Research, United Kingdom
Coronary Heart Disease
06/23
12/23
Steeds, Richard P
RaILRoAD, NCT03305250: Arrhythmia Burden, Risk of Sudden Cardiac Death and Stroke in Patients With Fabry Disease

Active, not recruiting
N/A
169
Europe, RoW
Implantable Loop Recorder
University Hospital Birmingham NHS Foundation Trust, Royal Free Hospital NHS Foundation Trust, Northern Care Alliance NHS Foundation Trust, University of Sydney, Cambridge University Hospitals NHS Foundation Trust, Cardiff and Vale University Health Board, Sheffield Teaching Hospitals NHS Foundation Trust
Fabry Disease
07/26
07/27
Newsome, Philip
NCT04442334: The European NAFLD Registry

Recruiting
N/A
10000
Europe
Newcastle University, Newcastle-upon-Tyne Hospitals NHS Trust, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Institute of Cardiometabolism and Nutrition, France, University of Cambridge, Örebro University, Sweden, University of Bern, University of Oxford, University of Turin, Italy, University of Angers, University Hospital, Antwerp, Linkoeping University, University of Helsinki, UMC Utrecht, National and Kapodistrian University of Athens, University of Lisbon, University of Milan, University of Palermo, Catholic University of the Sacred Heart, Wuerzburg University Hospital, RWTH Aachen University, University of Nottingham, Medical University of Vienna, University of Birmingham, University of Florence, Assistance Publique - Hôpitaux de Paris, University Medical Center Mainz
NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver, Steatosis of Liver, Hepatocellular Carcinoma, Cardiovascular Diseases, Type 2 Diabetes, Dyslipidaemia, Hypertension, Obesity, Other Associated Comorbidities
12/30
12/30
Roberts, Keith J
EMT2, NCT03428477 / 2016-000628-24: EPA for Metastasis Trial 2

Active, not recruiting
3
418
Europe
Icosapent Ethyl, Vascepa, Placebo
Mark A Hull, PhD FRCP, Yorkshire Cancer Research, Amarin Pharma Inc.
Liver Metastasis, Colon Cancer
11/25
04/26
DETECTION, NCT05980221: The Development of a Metabolomic Test to Diagnose and Quantify Pancreatic Exocrine Insufficiency (The Study)

Recruiting
N/A
150
Europe
Metabolomics, 13C MTGT, 13C MTG breath test
University Hospital Birmingham NHS Foundation Trust, Pancreatic Cancer UK
Pancreatic Exocrine Insufficiency
10/24
10/24
Moss, Paul
REACTIVAS, NCT04916704: Subclinical Cytomegalovirus Reactivation in Acute ANCA-associated Vasculitis

Active, not recruiting
N/A
70
Europe
University Hospital Birmingham NHS Foundation Trust, Merck Sharp & Dohme LLC
ANCA Associated Vasculitis
12/24
12/25
Ma, Yuk Ting
SAFIR-ABC10, NCT05615818: Personalized Medicine for Advanced Biliary Cancer Patients

Recruiting
3
800
Europe
Futibatinib, Ivosidenib, Tibsovo, Zanidatamab, Trastuzumab, Zercepac, Neratinib, Nerlynx, Encorafenib, Braftovi, Binimetinib, Mektovi, Niraparib, Zejula, Cisplatin, Gemcitabine
UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, National Cancer Institute, France, Cancer Research UK, Taiho Oncology, Inc., Servier, Zymeworks BC Inc., Accord Healthcare, Inc., Pierre Fabre Medicament
Biliary Tract Neoplasms
06/27
06/28
PRIMUS 001, NCT04151277 / ISRCTN75002153 / 2016-004155-67: A Study Looking at Two Different Chemotherapy Regimens in Patients With Metastatic Pancreatic Cancer

Recruiting
2
500
Europe
FOLFOX-A, Gemcitabe and Abraxane, G-CSF
Judith Dixon-Hughes, NHS Greater Glasgow and Clyde, University of Glasgow
Neoplasms Pancreatic
12/25
01/26
MATINS, NCT03733990 / 2018-002732-24: A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients

Completed
1/2
216
Europe, US
FP-1305 (bexmarilimab), bexmarilimab
Faron Pharmaceuticals Ltd
Cancer
09/23
10/23
NCT04161417: Precision-Panc Master Protocol: Personalising Treatment for Pancreatic Cancer

Recruiting
N/A
2500
Europe
Patients with suspected or confirmed pancreatic cancer will be be asked to provide biopsy material for molecular profiling
Judith Dixon-Hughes, Cancer Research UK, NHS Greater Glasgow and Clyde
Neoplasms Pancreatic
12/25
12/25
Perkins, Gavin
NCT03653832 / 2018-001650-98: Alpha 2 Agonists for Sedation to Produce Better Outcomes From Critical Illness (A2B Trial)

Completed
3
1437
Europe
Dexmedetomidine, Dexdor, Clonidine, Catapres, Propofol, Diprivan
University of Edinburgh, West Hertfordshire Hospitals NHS Trust, Queen's University, Belfast, The University of Queensland, University Hospital of Wales, Edinburgh Napier University, King's College London, University of Warwick, University of Manchester, Royal Surrey County Hospital NHS Foundation Trust, University College, London, NHS Lothian, Imperial College London, University of Cambridge
Critical Illness
12/23
07/24
PHIND, NCT04009330: Clinical Evaluation of a Point of Care (POC) Assay to Identify Phenotypes in the Acute Respiratory Distress Syndrome

Active, not recruiting
N/A
480
Europe
POC Assay
Queen's University, Belfast, Northern Ireland Clinical Trials Unit, Innovate UK
Acute Respiratory Distress Syndrome (ARDS)
11/23
02/26
Bhangu, Aneel
PROTECT-Surg, NCT04386070 / 2020-001448-24: Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19

Not yet recruiting
3
6400
NA
RESP301
University of Birmingham, Christian Medical College and Hospital, Ludhiana, India, Tamale Teaching Hospital, Ghana., University of Lagos, Nigeria, Kigali University Teaching Hospital, Hospital Español Veracruz, Université d'Abomey-Calavi, University of Witwatersrand, South Africa, University of Edinburgh, Istituto Clinico Humanitas, University of Cape Town
Pulmonary Complications in Surgical Patients, COVID, Severe Acute Respiratory Syndrome
05/22
05/26
TIGER, NCT06165133: Task Sharing in InGuinal hErnia Repair Between Surgeons and Non-surgeon Physicians

Not yet recruiting
N/A
1782
NA
Mesh inguinal hernia repair performed by Non-Surgeon Physicians (NSP), Mesh inguinal hernia repair performed by fully trained surgeons
University of Birmingham, Tamale Teaching Hospital, Ghana., University of Abomey Calavi, Benin
Inguinal Hernia
05/26
06/26
DRAGON, NCT06164444: Disposable Versus Reusable drApes and Gowns for Green OperatiNg Theatres

Not yet recruiting
N/A
26800
NA
Intervention: Reusable drapes and gowns, Comparator: Disposable (single-use) drapes and gowns
University of Birmingham, Christian Medical College, Vellore, India, Kigali University Teaching Hospital, Lagos State University, Hospital Español de Mexico, Christian Medical College and Hospital, Ludhiana, India, Centre National Hospitalier Universitaire Hubert Koutoukou MAGA, University for Development Studies, Tamale, Ghana, Chris Hani Baragwanath Academic Hospital
Surgical Site Infection
06/26
07/26
AlliGatOr, NCT06774001: A Global Prospective Cohort Study on Outcomes of Appendicectomy for Appendicitis

Not yet recruiting
N/A
14000
RoW
Appendicectomy
University of Birmingham, Christian Medical College and Hospital, Ludhiana, India, Tamale Teaching Hospital, Ghana., Lagos University Teaching Hospital (LUTH), Hospital Español Veracruz, WITS Health Consortium (South Africa), University of Abomey Calavi, Benin, Kigali University Teaching Hospital
Appendicitis, Appendectomy
07/25
12/25
CovidSurg-3, NCT05161299: Outcomes of Surgery in COVID-19 Infection

Not yet recruiting
N/A
2000
Europe
Surgery (across all specialities)
University of Birmingham
SARS-CoV-2 Infection, Surgery
02/22
03/22
Iqbal, Tariq
PSC-Vanc, NCT05376228: A Systems Biology Approach for Identification of Host and Microbial Mechanisms and Druggable Targets for the Treatment of PSC-IBD

Recruiting
N/A
15
Europe
Oral Vancomycin
University Hospital Birmingham NHS Foundation Trust
Inflammatory Bowel Diseases, Primary Sclerosing Cholangitis
02/23
04/23
Hirschfield, Gideon
NCT04950127 / 2021-000007-21: Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)

Active, not recruiting
3
238
Europe, Canada, Japan, US, RoW
Linerixibat, Placebo
GlaxoSmithKline
Pruritus
10/24
01/25
LLSAT, NCT04167358 / 2019-003158-10: Linerixibat Long-term Safety, and Tolerability Study

Recruiting
3
251
Europe, Canada, Japan, US, RoW
Linerixibat
GlaxoSmithKline, GlaxoSmithKline LLC, GlaxoSmithKline Research & Development Limited
Cholestasis
02/27
02/27
PACIFIC, NCT05525520 / 2021-002526-25: Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis

Completed
2
62
Europe, Canada, US, RoW
EP547, Placebo
Escient Pharmaceuticals, Inc, Escient Pharmaceuticals, Inc.
Pruritus
07/24
09/24
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
BELief, NCT06381453: Belimumab in Autoimmune Hepatitis

Recruiting
2
48
Canada
Belimumab Auto-Injector [Benlysta], Benlysta
University Health Network, Toronto, GlaxoSmithKline
Autoimmune Hepatitis
04/28
04/29
WIND-PSC, NCT06297993: Global Prospective, Observational Cohort of Adult Patients with Primary Sclerosing Cholangitis ( Study)

Recruiting
N/A
2000
Canada, US
PSC Partners Seeking a Cure
PSC
01/29
01/31
Dasgupta, Indranil
AIMHY-INFORM, NCT02847338: Comparison of Optimal Hypertension Regimens

Recruiting
4
1320
Europe
Amlodipine, Lisinopril, Amiloride, Chlortalidone
Cambridge University Hospitals NHS Foundation Trust, Medical Research Council
Hypertension
01/22
12/22
NCT06153693: Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

Active, not recruiting
3
1083
Europe, Canada, US, RoW
Placebo, lorundrostat Dose 1, lorundrostat Dose 2
Mineralys Therapeutics Inc.
Hypertension
12/24
02/25
PROTECT-V, NCT04870333 / 2020-004144-28: PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V

Recruiting
2/3
5000
Europe
Niclosamide, Placebo, Ciclesonide, Sotrovimab
Cambridge University Hospitals NHS Foundation Trust, Life Arc, Kidney Research UK (KRUK), UNION therapeutics, Addenbrookes Charitable Trust, GlaxoSmithKline, National Institute for Health Research, United Kingdom
Covid19
07/24
12/24
Turner, Alice
InnoVAATe, NCT04204252 / 2019-000602-30: Phase III, Efficacy and Safety of "Kamada-AAT for Inhalation"

Recruiting
3
220
Europe
Alpha 1-Antitrypsin, Kamada alpha 1-antitrypsin for inhalation, Placebo
Kamada, Ltd., Syneos Health
Alpha 1-Antitrypsin Deficiency
12/28
06/31
ELEVAATE, NCT05856331: Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema

Active, not recruiting
2
99
Europe, US, RoW
SAR447537, Zemaira, Respreeza
Sanofi
Alpha 1-Antitrypsin Deficiency, Emphysema
08/25
10/25
NCT04705233: Sputum Colour Charts to Guide Antibiotic Self-treatment of Acute Exacerbation of COPD (Colour COPD)

Recruiting
N/A
2954
Europe
sputum colour chart
University of Birmingham, Salford Royal Foundation Trust
Pulmonary Disease, Chronic Obstructive
03/23
12/23
Monksfield, Peter Mr
NCT05166265: Clinical Investigation Study of Safety and Performance of the Sentio System.

Active, not recruiting
N/A
51
Europe
Active transcutaneous bone conduction hearing system, Sentio system
Oticon Medical
Hearing Loss, Conductive, Hearing Loss, Mixed, Hearing Loss, Unilateral
02/24
11/25
Ma, Yuk-Ting
PRIMER-1, NCT05185739: Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)

Recruiting
2
60
Europe
Pembrolizumab, Lenvatinib, Pembrolizumab and Lenvatinib
University College, London, Merck Sharp & Dohme LLC
Hepatocellular Carcinoma
07/28
07/30
Glover, Richard M
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
NCT05490680: A New Sildenafil Oral Film in Patients With Erectile Dysfunction

Active, not recruiting
3
488
US
Sildenafil Oral Film 25 mg, 50 mg, 75 mg or 100 mg, Sildenafil Orodispersible Film, Placebo, Placebo-controlled
IBSA Institut Biochimique SA
Erectile Dysfunction
12/24
12/24
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
NCT06007183: Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination

Recruiting
3
800
US
CHIKV VLP vaccine booster, PXVX0317, Placebo booster
Bavarian Nordic
Chikungunya Virus Infection
04/28
08/28
NCT06039943: Relationship Between Acoustic Breath Sounds and Spirometry

Recruiting
N/A
200
Europe
Wheeze measurement
University Hospital Birmingham, Respiri US
Asthma COPD
08/24
08/24
Jacob, Saiju
NIMBLE, NCT05070858 / 2020-003272-41: A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

Recruiting
3
235
Europe, Canada, Japan, US, RoW
Pozelimab + Cemdisiran, Cemdisiran, ALN-CC5, Placebo, Pozelimab, REGN3918
Regeneron Pharmaceuticals
Generalized Myasthenia Gravis
05/25
03/28
Martin-Clavijo, Agustin
AMETHYST, NCT05531565 / 2020-000727-40: A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

Recruiting
2/3
474
Europe, Canada, Japan, US, RoW
Litifilimab, BIIB059, Placebo
Biogen, Biogen Idec Research Limited
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
10/26
12/27
SUMMERTIME, NCT04705389: SerUM Markers in MERkel Cell Carcinoma Patients: a Longitudinal moniTorIng Study for optiMization of European Guidelines

Not yet recruiting
N/A
150
Europe, RoW
Samples
University Hospital, Tours, European Academy of Dermatology and Venerology
Merkel Cell Carcinoma
09/21
09/23
MelMarT-II, NCT03860883: Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

Recruiting
N/A
2998
Europe, Canada, US, RoW
Wide Local Excision = 1cm Margin, Wide Local Excision = 2cm Margin
Melanoma and Skin Cancer Trials Limited, Norfolk and Norwich University Hospitals NHS Foundation Trust, Canadian Cancer Trials Group, Cancer Trials Ireland, Zuyderland Medical Centre
Cutaneous Melanoma, Stage II
12/29
12/34
Hanif, Wasim
NCT05189938: HbA1c Variation Study

Completed
N/A
488
Europe, US
HBA1c data and glucose levels
Abbott Diabetes Care
Diabetes Mellitus
12/23
12/23
Hiwot, Tarekegn
STAAR, NCT04046224 / 2019-000667-24: Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease

Active, not recruiting
1/2
34
Europe, Canada, US, RoW
ST-920
Sangamo Therapeutics
Fabry Disease
04/25
09/25
RaILRoAD, NCT03305250: Arrhythmia Burden, Risk of Sudden Cardiac Death and Stroke in Patients With Fabry Disease

Active, not recruiting
N/A
169
Europe, RoW
Implantable Loop Recorder
University Hospital Birmingham NHS Foundation Trust, Royal Free Hospital NHS Foundation Trust, Northern Care Alliance NHS Foundation Trust, University of Sydney, Cambridge University Hospitals NHS Foundation Trust, Cardiff and Vale University Health Board, Sheffield Teaching Hospitals NHS Foundation Trust
Fabry Disease
07/26
07/27
Gaucherite, NCT03240653: - A Study to Stratify Gaucher Disease

Recruiting
N/A
250
Europe
Stratified response to Enzyme Therapy, Stratified response to Substrate Reduction Therapy, Splenectormy
Cambridge University Hospitals NHS Foundation Trust, Medical Research Council, National Institute for Health Research, United Kingdom
Gaucher Disease, Type I, Gaucher Disease, Type III
09/28
12/28
Sutton, Benjamin
OCEAN, NCT05263934 / 2021-005726-15: Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)

Recruiting
3
160
Europe, Canada, Japan, US, RoW
Depemokimab, Mepolizumab, Placebo matching mepolizumab, Placebo matching depemokimab
GlaxoSmithKline
Eosinophilic Granulomatosis With Polyangiitis
10/25
11/25
 

Download Options